Inhibikase Therapeutics
IKT
21 hedge funds and large institutions have $7.78M invested in Inhibikase Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
50% more funds holding
Funds holding: 14 → 21 (+7)
1.21% more ownership
Funds ownership: 15.1% → 16.31% (+1.2%)
27% less capital invested
Capital invested by funds: $10.6M → $7.78M (-$2.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
+$304K |
| 2 |
Millennium Management
New York
|
+$228K |
| 3 |
AC
Antara Capital
New York
|
+$119K |
| 4 |
Bank of New York Mellon
New York
|
+$89.2K |
| 5 |
BlackRock
New York
|
+$83.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$307K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$144K |
| 3 |
HF
HRT Financial
New York
|
-$42K |
IKT Hedge Fund Activity: Q3 2021 in Review
21 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2021, worth a combined $7.78M — down 27% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IKT positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 1 trimmed.
The largest buyer was ACT Capital Management, adding an estimated $304K. The largest seller was Altium Capital Management, exiting entirely with an estimated $307K sold.
- 21 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2021, up from 14 in Q2 2021.
- Funds reported $7.78M of Inhibikase Therapeutics stock for Q3 2021, down 27% quarter-over-quarter.
- 9 funds opened new Inhibikase Therapeutics positions in Q3 2021 and 2 closed out, a net change of +7 holders.
- The largest Inhibikase Therapeutics buyer in Q3 2021 was ACT Capital Management, an estimated $304K added.
- The largest Inhibikase Therapeutics seller in Q3 2021 was Altium Capital Management, an estimated $307K sold.
Based on aggregated 13F filings for Q3 2021.